Mitozantrone
Therapeutic agent (verify pharmacological class)
What it is used for
Acute myeloid (myelogenous, nonlymphocytic) leukemia in adults; hormone-refractory prostate cancer. (In combination with other chemotherapeutic agents) Clinical selection for Mitozantrone should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
Warnings
Only physicians experienced in cancer chemotherapy should use it; increased incidence of infections; to reduce the dose in case of impaired hepatic function; severe myelosuppression with resulting infection or bleeding may occur; cardiac function should be monitored regularly.
Possible side effects
Myelosuppression; cardiac toxicity and congestive heart failure; triad of back pain; flushing; and chest tightness; increased appetite; dysphagia; GI haemorrhage; gastritis; stomatitis; nausea and vomiting; gingival bleeding; hemorrhoids; melena; diarrhea; abdominal pain; anorexia; and constipation; dry mouth; taste perversion; thirst; hiccups; or tooth caries; neuropathy; amnesia; anxiety; ataxia; confusion; emotional lability; hallucination; hyperkinesias; hypertonia; tremor; somnolence; seizures; alopecia; pigmentation of fingernails and toenails; severe local tissue dam-age in extravasation; fever; myalgia; hypocalcaemia; hypersensitivity reactions; colouring of urine blue-green for 24 hours after administration.
Storage
Store as labelled. Keep out of reach of children.
No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.